CRISPR Therapeutics AG
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| C2RS34.SA | NTLA | SANA | SCTX | EDIT | PGEN | |
|---|---|---|---|---|---|---|
| Market cap | 3.36B | 1.72B | 766.36M | 317.67M | 417.74M | 1.81B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | -4.8 | -4.6 | -4.6 | -3.6 | -23.0 |
| Price/book | 0.4 | 2.4 | 5.0 | -0.3 | 4.0 | 85.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +6.71% | −0.08% | −36.79% | −11.54% | +1.12% | +29.08% |
| Today | 0.00% | +3.79% | +4.92% | +3.58% | +4.62% | −3.71% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All C2RS34.SA news ›Crispr Therapeutics AG (CRSP) Receives a Hold from RBC Capital
In a report released yesterday, Luca Issi from RBC Capital maintained a Hold rating on Crispr Therapeutics AG, with a price target of $50.00. According to TipRanks, Issi is an analyst with an average return of -5.6% and a 36.64% success…
Analysts’ Top Healthcare Picks: Crispr Therapeutics AG (CRSP), Faeth Therapeutics (FTH)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Crispr Therapeutics AG (CRSP) and Faeth Therapeutics (FTH) with bullish sentiments. Crispr Therapeutics AG (CRSP) In a report released today,…
CRISPR Therapeutics (NASDAQ:CRSP) Stock Gets Price Target Boost from Citigroup
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) had its target price boosted by stock analysts at Citigroup from $88.00 to $90.00 in a report issued on Wednesday, Benzinga reports. The firm presently has a "buy" rating on the stock.…
CRISPR Therapeutics AG $CRSP Stock Sold by Sumitomo Mitsui Trust Group Inc.
Check Out Our Latest Research Report on CRISPR Therapeutics Here are the key news stories impacting CRISPR Therapeutics this week: Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex…
Head-To-Head Comparison: CRISPR Therapeutics (NASDAQ:CRSP) vs. Rallybio (NASDAQ:RLYB)
Posted by Tristan Rich on Nov 4th, 2026 CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) and Rallybio (NASDAQ:RLYB – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses…
CRISPR Therapeutics to present clinical data on gene-edited CAR T therapy for lymphoma at ASH 2026
CRISPR Therapeutics announced it will present clinical trial data for zugocabtagene geleucel (zugo-cel), an allogeneic CRISPR/Cas9 gene-edited CAR T cell therapy targeting CD19, at the 68th ASH Annual Meeting in December 2026. The therapy…
CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition
CRISPR Therapeutics to Present Clinical Data from Zugo-cel GlobeNewswire
CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer
markets.businessinsider.com CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer ZUG, Switzerland and BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR The
CRISPR Therapeutics Q3 CASGEVY Revenue Reaches $99 Million
CRISPR Therapeutics (CRSP ) reported third-quarter 2026 results on November 2, 2026 for the quarter ended September 30, 2026, posting CASGEVY revenue of $99 million and a net loss of $111.4 million, compared with a $106.4 million loss a…
CRISPR Therapeutics AG Announces CFO Changes
CRISPR Therapeutics AG announced the promotion of Andrew J. Silver, currently the Company's SVP, Finance, to be the Company's Chief Financial Officer effective October 19, 2026. Since January 2025,... CRISPR Therapeutics AG announced the…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- markets.businessinsider.com9
- marketscreener.com7
- stocktitan.net6
- fool.com5
- themarketsdaily.com5
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 61 articles, not a forecast.